We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Protein Biomarkers Predict Outcome of a Patient’s COVID-19 Infection

By LabMedica International staff writers
Posted on 08 Jun 2020
A panel of blood biomarkers in patients with COVID-19 has demonstrated the potential to predict the severity of their symptoms and likely outcome of the infection.

By the beginning of June 2020 more than six million people worldwide had become ill with COVID-19, caused by the SARS-CoV-2 coronavirus, and more than 380,000 had perished. More...
Thus, a method to predict the likely trajectory of the disease in the individual patient is an urgent requirement.

Toward this end, investigators at the Francis Crick Institute (London, UK) and Charité – Universitätsmedizin Berlin (Germany) developed a platform for ultra-high throughput serum and plasma proteomics (protein analysis). This method was designed to adhere to ISO13485 standardization for MS-high-flow liquid chromatography to facilitate implementation in clinical laboratories.

The platform was developed at the Francis Crick Institute and applied to analyze serum of 31 COVID-19 patients at the Berlin University Hospital Charité. Results were further validated in 17 patients with COVID-19 at the same hospital and in 15 healthy individuals.

Results of the analyses identified 27 potential biomarkers in the blood that were differentially expressed depending on the WHO severity grade of COVID-19. The biomarkers included complement factors, components of the coagulation system, inflammation modulators, and pro-inflammatory proteins upstream and downstream of interleukin. The low-cost workflow quantified 180 proteomes per day per mass spectrometer, enabled high precision quantification, and reduced batch effects for large-scale and longitudinal studies.

Senior author Dr. Markus Ralser, group leader at the Francis Crick Institute and professor of biochemistry at Charité – Universitätsmedizin Berlin, said, "The robust method we have used in this study is a valuable and powerful tool to predict disease progression and also find potential targets for treatments. Our approach could also be easily applied to other diseases, now and in the future, to understand more about their effects on the body."

The COVID-19 blood biomarker study was published in the May 2020 online edition of the journal Cell Systems.

Related Links:
Francis Crick Institute
Charité – Universitätsmedizin Berlin



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.